ProCE Banner Activity

SWOG 1211: Phase I/II Trial of Elotuzumab + RVd vs RVd Alone in Newly Diagnosed, High-Risk Myeloma

Slideset Download
Conference Coverage
Addition of elotuzumab to RVd induction and maintenance therapy did not improve outcomes in patients with high-risk multiple myeloma

Released: June 01, 2020

Expiration: May 31, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono